来自官方财务报表的收入、利润与现金流历史。
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹335.9B | ₹325.5B | ₹279.2B | ₹245.9B | — |
| 毛利 | ₹177.3B | ₹190.4B | ₹163.6B | ₹139.3B | — |
| 营业利润（EBIT） | ₹50.1B | ₹72.0B | ₹65.3B | ₹59.1B | — |
| 净利 | ₹42.9B | ₹56.5B | ₹55.7B | ₹45.1B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 DRREDDY 交互式查看器。 /companies/us/DRREDDY
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms